Eton Pharmaceutcials, Inc. Common Stock (ETON)

Price$28.68

Value ScoreD

Growth ScoreA

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)70.88%

Price vs S&P 500 (4W)0.39%

VGM Score59.78

Market Capitalization$834.10M

All Metrics

P/CF (Annual)79.26x

Book Value / Share (Quarterly)$1.12

P/TBV (Annual)10.47x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)55.53%

Cash Flow / Share (Quarterly)$0.02

Price vs S&P 500 (YTD)69.14%

Gross Margin (TTM)54.77%

Net Profit Margin (TTM)-1.70%

EPS (TTM)$-0.06

10-Day Avg Trading Volume0.46M

EPS Excl Extra (TTM)$-0.06

Revenue Growth (5Y)357.25%

EPS (Annual)$-0.17

ROI (Annual)-8.11%

Gross Margin (Annual)53.46%

Net Profit Margin (5Y Avg)-13.99%

Cash / Share (Quarterly)$0.72

Revenue Growth QoQ (YoY)40.41%

ROA (Last FY)-4.99%

Revenue Growth TTM (YoY)79.89%

EBITD / Share (TTM)$0.22

ROE (5Y Avg)-23.87%

Operating Margin (TTM)2.35%

Cash Flow / Share (Annual)$0.38

P/B Ratio27.24x

P/B Ratio (Quarterly)22.00x

Net Income / Employee (Annual)$-104,600

EV / Revenue (TTM)9.72x

Net Interest Coverage (TTM)-0.23x

ROA (TTM)-1.49%

EV / EBITDA (TTM)136.28x

EPS Incl Extra (Annual)$-0.17

Current Ratio (Annual)1.57x

Quick Ratio (Quarterly)0.75x

3-Month Avg Trading Volume0.37M

52-Week Price Return60.94%

EV / Free Cash Flow (Annual)82.93x

Revenue / Employee (TTM)$1,975,800

Tangible BV / Share (Quarterly)$0.39

P/S Ratio (Annual)10.43x

Asset Turnover (Annual)0.87x

52-Week High$35.66

Operating Margin (5Y Avg)-11.57%

EPS Excl Extra (Annual)$-0.17

CapEx CAGR (5Y)46.12%

Tangible BV CAGR (5Y)-7.25%

26-Week Price Return86.81%

Quick Ratio (Annual)0.98x

13-Week Price Return76.52%

Total Debt / Equity (Annual)1.17x

Current Ratio (Quarterly)1.21x

Enterprise Value$845.18M

Revenue / Share Growth (5Y)335.35%

Asset Turnover (TTM)0.88x

Book Value / Share Growth (5Y)8.46%

Revenue / Employee (Annual)$1,817,000

Inventory Turnover (Annual)2.43x

Pretax Margin (Annual)-5.70%

Cash / Share (Annual)$0.96

3-Month Return Std Dev71.02%

Gross Margin (5Y Avg)66.90%

Net Income / Employee (TTM)$-33,500

EBITDA Interim CAGR (5Y)-8.48%

ROE (Last FY)-17.59%

Net Interest Coverage (Annual)0.58x

EPS Basic Excl Extra (Annual)$-0.17

P/FCF (TTM)38.28x

Receivables Turnover (TTM)5.83x

EV / Free Cash Flow (TTM)1960.98x

Total Debt / Equity (Quarterly)1.00x

EPS Incl Extra (TTM)$-0.06

Receivables Turnover (Annual)9.34x

ROI (TTM)-2.61%

P/S Ratio (TTM)9.59x

Pretax Margin (5Y Avg)-13.81%

Revenue / Share (Annual)$2.97

Tangible BV / Share (Annual)$0.42

Forward P/E27.72x

Price vs S&P 500 (52W)32.73%

Year-to-Date Return80.07%

5-Day Price Return-6.57%

EPS Normalized (Annual)$-0.17

ROA (5Y Avg)-11.23%

Net Profit Margin (Annual)-5.75%

Month-to-Date Return26.24%

Cash Flow / Share (TTM)$0.12

EBITD / Share (Annual)$0.12

Operating Margin (Annual)-1.06%

LT Debt / Equity (Annual)0.83x

P/CF (TTM)52.66x

ROI (5Y Avg)-14.79%

LT Debt / Equity (Quarterly)0.62x

EPS Basic Excl Extra (TTM)$-0.06

P/TBV (Quarterly)15.31x

P/B Ratio (Annual)17.34x

Inventory Turnover (TTM)2.80x

Pretax Margin (TTM)-1.71%

Book Value / Share (Annual)$0.97

Price vs S&P 500 (13W)66.78%

Beta0.90x

P/FCF (Annual)81.85x

Revenue / Share (TTM)$2.76

ROE (TTM)-5.68%

52-Week Low$13.09

vGradeD

gGradeA

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 260.05est. 0.09

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.11

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ETONEton Pharmaceutcials, Inc. Common Stock	D	A	B	$28.68
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Eton Pharmaceuticals is a specialty pharmaceutical company focused on rare diseases with significant unmet patient needs. The company markets four FDA-approved products addressing adrenocortical insufficiency, hyperammonemia, homocystinuria, and hereditary tyrosinemia type 1. Eton is advancing three late-stage product candidates, including an innovative hydrocortisone autoinjector, to expand its rare disease portfolio.